Effect of salmetrol-fluticason combination and tiotropium on clinical and physiological improvement of bronchial anthracofibrosis, a double blind randomized, cross over, placebo controlled, clinical trial.

M. Mirsadraei (Mashhad, Islamic Republic of Iran)

Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology
Session: Towards better treatments for lung disease: experimental pharmacology
Session type: Thematic Poster
Number: 1037
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Mirsadraei (Mashhad, Islamic Republic of Iran). Effect of salmetrol-fluticason combination and tiotropium on clinical and physiological improvement of bronchial anthracofibrosis, a double blind randomized, cross over, placebo controlled, clinical trial.. 1037

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
A single centre, double blind, double dummy, placebo controlled, randomized, three period cross-over phase III trial to demonstrate therapeutic equivalence between a generic and branded inhalation product of ipratropium bromide in subjects with
Source: Eur Respir J 2001; 18: Suppl. 33, 71s
Year: 2001

Short-term effect of a single dose of inhaled procaterol on exercise performance in COPD: a randomized, double blind, placebo-controlled, crossover trial
Source: Annual Congress 2008 - Physiological response to exercise performance
Year: 2008


A multicenter, randomized, double-blind, double-dummy, 2-way crossover, single dose study, comparing the efficacy and safety of the fluticasone/salmeterol (500/50 μg) combination administered with the new Elpenhaler inhalation device versus the innovative one in patients with asthma
Source: Annual Congress 2009 - Quality of treatment in primary respiratory care
Year: 2009

Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial.
Source: International Congress 2018 – New developments in the treatment of asthma
Year: 2018


Paracetamol increases airway resistance in stable asthmatics: A double blind, randomized, placebo controlled study
Source: Annual Congress 2010 - New or old physiological parameters in chronic airway disorders?
Year: 2010


Glycopyrrolate MDI demonstrates comparable efficacy and safety to tiotropium DPI in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Year: 2011

Comparison of efficacy and safety of two HFA formulations of fluticasone propionate; a double-blind, randomised, multicentric, parallel group study in patients with persistent moderate asthma
Source: Annual Congress 2009 - New aspects of inhalation therapy
Year: 2009

A randomized placebo controlled trial of AZD8871 a novel dual acting bronchodilator in asthmatics.
Source: International Congress 2017 – Bronchodilators and bronchoprotectors
Year: 2017

Acetylcysteine in treatment of subacute sinusitis, a double blind placebo controlled clinical trial study
Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections
Year: 2010


A randomized placebo controlled trial of AZD8999 (LAS190792) a novel dual acting bronchodilator in asthmatics
Source: International Congress 2017 – Novel studies on bronchodilators and cough
Year: 2017



The effect of high dose N-acetylcysteine (1200mg daily) on airway function and airway trapping in COPD patients — A double blinded randomized placebo controlled trial
Source: Annual Congress 2012 - COPD treatments: efficacy and safety
Year: 2012


A double-blind double dummy randomised placebo-controlled cross-over design clinical trial of formoterol delivered by two different dry powder devices in prevention of bronchoconstriction induced by methacholine in mild to moderate persistent asthma in adult patients
Source: Annual Congress 2009 - Airway hyperresponsiveness: mechanism and assessment
Year: 2009

Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial
Source: Eur Respir J, 54 (4) 1901030; 10.1183/13993003.01030-2019
Year: 2019



Late Breaking Abstract - A randomised, double-blind, placebo controlled, clinical trial evaluating imatinib in patients with severe COVID-19
Source: Virtual Congress 2021 – Late breaking basic and translational science of SARS-Cov2 and COVID-19
Year: 2021



The evaluation of the efficacy and safety of phospholipids‘ inhalation in patients with bronchial asthma (BA): A prospective randomized placebo-controlled study
Source: Annual Congress 2012 - Asthma treatment: efficacy and safety
Year: 2012

Clinical effectiveness of MDI-HFA-Modulite budesonide in the treatment of asthma – meta-analysis of randomised controlled trials
Source: Eur Respir J 2006; 28: Suppl. 50, 315s
Year: 2006

Effect of borago extract on moderate persistent asthma, a phase two randomized, double blind placebo-controlled clinical trial
Source: International Congress 2016 – Asthma management
Year: 2016


A randomized, double blind, cross-over study to investigate the pharmacodynamic equivalence of salbutamol administered via a new HFA134 inhaler versus Evohaler in mild stable asthmatics
Source: Eur Respir J 2006; 28: Suppl. 50, 210s
Year: 2006

Effect of reflexology, homeopathy, and traditional medical treatment in asthma: A randomised, controlled, parallel-group trial
Source: Annual Congress 2010 - Questionnaires use and psychological aspects in asthma
Year: 2010